Editor's Note: The Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in Jinan. This conference brought together authoritative experts in the field of oncology from home and…

The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O'Connor, delivered a splendid presentation on the topic "REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL BASIS COMES INTO FOCUS." He systematically reviewed the historical challenges in the treatment of T-cell lymphoma and emphatically elaborated on why epigenetic targeting will be the key to turning the tide, pointing to a hopeful new path for the future treatment of this disease.

The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong, from September 10 to 14, 2025, under the theme “Standardized Treatment, Innovation-Driven Progress.” The meeting gathered leading scholars from China and abroad for a major exchange of ideas. In the field of breast cancer, Professor Giuseppe Curigliano, President-Elect of the European Society for Medical Oncology (ESMO) and Professor at the University of Milan, shared the revolutionary progress of antibody-drug conjugates (ADCs). Professor Zefei Jiang, President-Elect of CSCO and oncologist at the General Hospital of the PLA, presented Chinese subgroup data from the DESTINY-Breast09 (DB09) study, which investigated first-line treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab for HER2-positive advanced breast cancer, highlighting the bright future of ADC therapy. The two experts sat down with Oncology Frontier to discuss the promising outlook for CSCO–ESMO collaboration and to interpret the clinical impact of DESTINY-Breast09.